Biostar Pharmaceuticals, Inc. Provides Update Regarding Gel Capsule Safety Issues
XIANYANG, China, May 30, 2012 /PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that, following an onsite inspection by Xianyang's State Food and Drug Administration (SFDA), samples from a batch of its Xin Aoxing capsules were found to contain a chromium content higher than edible gelatin, which capsules, in the Company's estimation, were sold in the PRC market in mid-2011.
As previously announced, on April 27, 2012, SFDA launched an investigation of several capsule manufacturers based in Zhejiang, Hebei and Jiangxi provinces into their use of industrial gelatin, which contains impermissibly high chromium content. On May 25, 2012, following a nationwide inspection, SFDA authorities reported that 669 batches of gel capsules from 254 drug manufacturers in 28 provinces were found to have high chromium levels. The results of this inspection were published on SFDA's website http://www.sda.gov.cn/WS01/CL0001.
As required by SFDA in April 2012, the Company purchased gel capsule inspection equipment to measure the chromium levels in gel capsules it used. The Company also undertook a thorough inspection of all samples of drugs sold and its current product inventory to ensure that all of the gel capsules it had purchased and currently uses comply with the SFDA chromium content requirements. In addition, the Company conducted checks of every batch of raw materials it uses in every production category and, except as discussed below, found no violations of the chromium content requirements.
Ronghua Wang, Biostar's Chief Executive Officer and Chairman commented, "On May 25, 2012 we were informed by the Xianyang SFDA that samples from a batch of 150 cases of the Xin Aoxing capsules (each of the 150 cases contains 8,000 capsules), representing Biostar sales of approximately 1,188,000 RMB or approximately $188,000 were also found to contain high levels of chromium. Additionally, during our own contemporaneously conducted inspection on May 22, 2012, samples from 3 batches of 380 cases of the Tianqi capsules were found to have high chromium levels (each of the 380 cases contains 7,200 capsules), representing Biostar sales of approximately 230,000 RMB or approximately $36,000, which capsules, in the Company's estimation, were sold in the market in mid-2011."
He continued, "Once the Company's management was notified by the Xianyang SFDA about the batch of the gel capsules in question, we urgently convened to, among other things: (i) identify the source of the tainted capsule batch, (ii) recall all such capsules as promptly and thoroughly as possible, and (iii) review and impose heightened quality control and assurance measures going forward. During our review, we determined that the capsule batch in question was purchased in May 2011 by one of our formerly employed purchasing managers who, in disregard of the Company's policies, purchased 4 million capsules from a non-approved supplier. Due to this incident, his employment with the Company was terminated in August 2011, immediately after we had become aware of this purchase. The Company did not check the batch in question for the chromium levels at that time since PRC pharmaceutical companies were not required to test their gel capsule inventories and purchases for chromium levels in 2011."
Mr. Wang continued, "Upon learning of the gel capsule batch in question containing high chromium levels, we immediately sent recall notices to all of our distribution centers and notified local SFDA offices in all provinces where our sales are made. Each distribution center is required to report to the Company's management daily about the progress made in recalling all batches found to be manufactured using the tainted gel capsules.
"In addition, our Quality Control staff is in process of completing a self-administered inspection of all drugs utilizing capsules as delivery method and capsule samples acquired during the period from June 2009 to April 2012. We anticipate completing this process by May 31, 2012. We intend to announce the results of this self-administered inspection in middle of June, when Xianyang SFDA, in turn, reviews and approves the conclusions of our inspection."
Mr. Wang concluded, "The tainted capsule batch in question acquired in May 2011 was purchased as a result of the unauthorized actions of our former employee who bypassed our regular supply purchasing protocol and procedures. While we believe that our quality control and purchasing practices are adequately suited to address our needs, we have been and remain fully committed to complying with all applicable SFDA directives as well as bolstering our internal quality assurance measures. We have invested in additional testing equipment, and increased the frequency and depth of our self-administered inspections of our inventory and supplies."
As reported by SFDA and published in a major local newspaper, Huashang News (www.hsw.cn) on May 26, 2012, the results of the SFDA investigation indicate that gel capsules containing drugs of all of China's pharmaceutical companies distributed after May 1, 2012 are made with edible gelatin, do not have high chromium levels and are safe to use.
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com
Safe Harbor relating to the Forward-Looking Statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to recover its sales following the SFDA investigation, the Company's ability to identify and recall all the tainted capsules, the Company's ability to provide future safety and compliance assurances, the state of consumer confidence and market demand or the Company's products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.
SOURCE Biostar Pharmaceuticals, Inc.